Annovis Bio (NYSE:ANVS) announced the publication of three granted U.S. patents that cover methods of treating amyloid lateral sclerosis, Huntington’s disease, and prion diseases by administering buntanetap.
The patents will provide intellectual property protection through 2031, prior to any patent extensions.
“These additional patents represent further proof for our platform drug, buntanetap, which acts on a variety of neurodegenerative disorders by inhibiting multiple neurotoxic proteins,” Maria Maccecchini, Ph.D., founder, president, and CEO of Annovis.
The key coverage includes:
- A method of treating amyloid lateral sclerosis by administering buntanetap and inhibiting the synthesis of superoxide dismutase protein1 and TDP43.
- A method of treating Huntington’s disease by administering buntanetap and inhibiting the synthesis of Huntingtin protein.
- A method of treating prion diseases, a family of ultra-rare progressive neurodegenerative disorders, by administering buntanetap. There is additional coverage of particular prion diseases, including scrapie prion, transmissible mink encephalopathy, chronic wasting disease, bovine spongiform encephalopathy prion, feline spongiform encephalopathy, exotic ungulate encephalopathy, kuru prion, Creutzfeldt-Jakob disease, variant Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia prion.
